Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

Organoid cultures recapitulate esophageal adenocarcinoma heterogeneity providing a model for clonality studies and precision therapeutics.

Li X, Francies HE, Secrier M, Perner J, Miremadi A, Galeano-Dalmau N, Barendt WJ, Letchford L, Leyden GM, Goffin EK, Barthorpe A, Lightfoot H, Chen E, Gilbert J, Noorani A, Devonshire G, Bower L, Grantham A, MacRae S, Grehan N, Wedge DC, Fitzgerald RC, Garnett MJ.

Nat Commun. 2018 Jul 30;9(1):2983. doi: 10.1038/s41467-018-05190-9.

2.

Erratum to: Drug Sensitivity Assays of Human Cancer Organoid Cultures.

Francies HE, Barthorpe A, McLaren-Douglas A, Barendt WJ, Garnett MJ.

Methods Mol Biol. 2018 Mar 27. doi: 10.1007/7651_2018_138. [Epub ahead of print] No abstract available.

PMID:
30006863
3.

Itraconazole targets cell cycle heterogeneity in colorectal cancer.

Buczacki SJA, Popova S, Biggs E, Koukorava C, Buzzelli J, Vermeulen L, Hazelwood L, Francies H, Garnett MJ, Winton DJ.

J Exp Med. 2018 Jul 2;215(7):1891-1912. doi: 10.1084/jem.20171385. Epub 2018 May 31.

4.

The Origins and Vulnerabilities of Two Transmissible Cancers in Tasmanian Devils.

Stammnitz MR, Coorens THH, Gori KC, Hayes D, Fu B, Wang J, Martin-Herranz DE, Alexandrov LB, Baez-Ortega A, Barthorpe S, Beck A, Giordano F, Knowles GW, Kwon YM, Hall G, Price S, Pye RJ, Tubio JMC, Siddle HVT, Sohal SS, Woods GM, McDermott U, Yang F, Garnett MJ, Ning Z, Murchison EP.

Cancer Cell. 2018 Apr 9;33(4):607-619.e15. doi: 10.1016/j.ccell.2018.03.013.

5.

Discovery of Potent and Selective MRCK Inhibitors with Therapeutic Effect on Skin Cancer.

Unbekandt M, Belshaw S, Bower J, Clarke M, Cordes J, Crighton D, Croft DR, Drysdale MJ, Garnett MJ, Gill K, Gray C, Greenhalgh DA, Hall JAM, Konczal J, Lilla S, McArthur D, McConnell P, McDonald L, McGarry L, McKinnon H, McMenemy C, Mezna M, Morrice NA, Munro J, Naylor G, Rath N, Schüttelkopf AW, Sime M, Olson MF.

Cancer Res. 2018 Apr 15;78(8):2096-2114. doi: 10.1158/0008-5472.CAN-17-2870. Epub 2018 Jan 30.

PMID:
29382705
6.

Perturbation-response genes reveal signaling footprints in cancer gene expression.

Schubert M, Klinger B, Klünemann M, Sieber A, Uhlitz F, Sauer S, Garnett MJ, Blüthgen N, Saez-Rodriguez J.

Nat Commun. 2018 Jan 2;9(1):20. doi: 10.1038/s41467-017-02391-6.

7.

Transcription Factor Activities Enhance Markers of Drug Sensitivity in Cancer.

Garcia-Alonso L, Iorio F, Matchan A, Fonseca N, Jaaks P, Peat G, Pignatelli M, Falcone F, Benes CH, Dunham I, Bignell G, McDade SS, Garnett MJ, Saez-Rodriguez J.

Cancer Res. 2018 Feb 1;78(3):769-780. doi: 10.1158/0008-5472.CAN-17-1679. Epub 2017 Dec 11.

PMID:
29229604
8.

GDSCTools for mining pharmacogenomic interactions in cancer.

Cokelaer T, Chen E, Iorio F, Menden MP, Lightfoot H, Saez-Rodriguez J, Garnett MJ.

Bioinformatics. 2018 Apr 1;34(7):1226-1228. doi: 10.1093/bioinformatics/btx744.

9.

Single agent and synergistic combinatorial efficacy of first-in-class small molecule imipridone ONC201 in hematological malignancies.

Prabhu VV, Talekar MK, Lulla AR, Kline CLB, Zhou L, Hall J, Van den Heuvel APJ, Dicker DT, Babar J, Grupp SA, Garnett MJ, McDermott U, Benes CH, Pu JJ, Claxton DF, Khan N, Oster W, Allen JE, El-Deiry WS.

Cell Cycle. 2018;17(4):468-478. doi: 10.1080/15384101.2017.1403689. Epub 2018 Feb 19.

PMID:
29157092
10.

Human primary liver cancer-derived organoid cultures for disease modeling and drug screening.

Broutier L, Mastrogiovanni G, Verstegen MM, Francies HE, Gavarró LM, Bradshaw CR, Allen GE, Arnes-Benito R, Sidorova O, Gaspersz MP, Georgakopoulos N, Koo BK, Dietmann S, Davies SE, Praseedom RK, Lieshout R, IJzermans JNM, Wigmore SJ, Saeb-Parsy K, Garnett MJ, van der Laan LJ, Huch M.

Nat Med. 2017 Dec;23(12):1424-1435. doi: 10.1038/nm.4438. Epub 2017 Nov 13.

11.

High-throughput RNAi screen for essential genes and drug synergistic combinations in colorectal cancer.

Williams SP, Barthorpe AS, Lightfoot H, Garnett MJ, McDermott U.

Sci Data. 2017 Oct 3;4:170139. doi: 10.1038/sdata.2017.139.

12.

Cancer stem cell-related gene expression as a potential biomarker of response for first-in-class imipridone ONC201 in solid tumors.

Prabhu VV, Lulla AR, Madhukar NS, Ralff MD, Zhao D, Kline CLB, Van den Heuvel APJ, Lev A, Garnett MJ, McDermott U, Benes CH, Batchelor TT, Chi AS, Elemento O, Allen JE, El-Deiry WS.

PLoS One. 2017 Aug 2;12(8):e0180541. doi: 10.1371/journal.pone.0180541. eCollection 2017.

13.

A Road Map for Precision Cancer Medicine Using Personalized Models.

Picco G, Garnett MJ.

Cancer Discov. 2017 May;7(5):456-458. doi: 10.1158/2159-8290.CD-17-0268.

14.

Drug Resistance Mechanisms in Colorectal Cancer Dissected with Cell Type-Specific Dynamic Logic Models.

Eduati F, Doldàn-Martelli V, Klinger B, Cokelaer T, Sieber A, Kogera F, Dorel M, Garnett MJ, Blüthgen N, Saez-Rodriguez J.

Cancer Res. 2017 Jun 15;77(12):3364-3375. doi: 10.1158/0008-5472.CAN-17-0078. Epub 2017 Apr 5.

15.

Logic models to predict continuous outputs based on binary inputs with an application to personalized cancer therapy.

Knijnenburg TA, Klau GW, Iorio F, Garnett MJ, McDermott U, Shmulevich I, Wessels LF.

Sci Rep. 2016 Nov 23;6:36812. doi: 10.1038/srep36812.

16.

A Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer Compounds.

Bruna A, Rueda OM, Greenwood W, Batra AS, Callari M, Batra RN, Pogrebniak K, Sandoval J, Cassidy JW, Tufegdzic-Vidakovic A, Sammut SJ, Jones L, Provenzano E, Baird R, Eirew P, Hadfield J, Eldridge M, McLaren-Douglas A, Barthorpe A, Lightfoot H, O'Connor MJ, Gray J, Cortes J, Baselga J, Marangoni E, Welm AL, Aparicio S, Serra V, Garnett MJ, Caldas C.

Cell. 2016 Sep 22;167(1):260-274.e22. doi: 10.1016/j.cell.2016.08.041. Epub 2016 Sep 15.

17.

Drug Sensitivity Assays of Human Cancer Organoid Cultures.

Francies HE, Barthorpe A, McLaren-Douglas A, Barendt WJ, Garnett MJ.

Methods Mol Biol. 2016 Sep 15. [Epub ahead of print] Erratum in: Methods Mol Biol. 2018 Mar 27;:.

PMID:
27628132
18.

A Landscape of Pharmacogenomic Interactions in Cancer.

Iorio F, Knijnenburg TA, Vis DJ, Bignell GR, Menden MP, Schubert M, Aben N, Gonçalves E, Barthorpe S, Lightfoot H, Cokelaer T, Greninger P, van Dyk E, Chang H, de Silva H, Heyn H, Deng X, Egan RK, Liu Q, Mironenko T, Mitropoulos X, Richardson L, Wang J, Zhang T, Moran S, Sayols S, Soleimani M, Tamborero D, Lopez-Bigas N, Ross-Macdonald P, Esteller M, Gray NS, Haber DA, Stratton MR, Benes CH, Wessels LFA, Saez-Rodriguez J, McDermott U, Garnett MJ.

Cell. 2016 Jul 28;166(3):740-754. doi: 10.1016/j.cell.2016.06.017. Epub 2016 Jul 7.

19.

Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma.

Saha SK, Gordan JD, Kleinstiver BP, Vu P, Najem MS, Yeo JC, Shi L, Kato Y, Levin RS, Webber JT, Damon LJ, Egan RK, Greninger P, McDermott U, Garnett MJ, Jenkins RL, Rieger-Christ KM, Sullivan TB, Hezel AF, Liss AS, Mizukami Y, Goyal L, Ferrone CR, Zhu AX, Joung JK, Shokat KM, Benes CH, Bardeesy N.

Cancer Discov. 2016 Jul;6(7):727-39. doi: 10.1158/2159-8290.CD-15-1442. Epub 2016 May 26.

20.

Multilevel models improve precision and speed of IC50 estimates.

Vis DJ, Bombardelli L, Lightfoot H, Iorio F, Garnett MJ, Wessels LF.

Pharmacogenomics. 2016 May;17(7):691-700. doi: 10.2217/pgs.16.15. Epub 2016 May 16.

PMID:
27180993
21.

Identification of differential PI3K pathway target dependencies in T-cell acute lymphoblastic leukemia through a large cancer cell panel screen.

Lynch JT, McEwen R, Crafter C, McDermott U, Garnett MJ, Barry ST, Davies BR.

Oncotarget. 2016 Apr 19;7(16):22128-39. doi: 10.18632/oncotarget.8031.

22.

Exploitation of the Apoptosis-Primed State of MYCN-Amplified Neuroblastoma to Develop a Potent and Specific Targeted Therapy Combination.

Ham J, Costa C, Sano R, Lochmann TL, Sennott EM, Patel NU, Dastur A, Gomez-Caraballo M, Krytska K, Hata AN, Floros KV, Hughes MT, Jakubik CT, Heisey DA, Ferrell JT, Bristol ML, March RJ, Yates C, Hicks MA, Nakajima W, Gowda M, Windle BE, Dozmorov MG, Garnett MJ, McDermott U, Harada H, Taylor SM, Morgan IM, Benes CH, Engelman JA, Mossé YP, Faber AC.

Cancer Cell. 2016 Feb 8;29(2):159-72. doi: 10.1016/j.ccell.2016.01.002.

23.

Integration of genomic, transcriptomic and proteomic data identifies two biologically distinct subtypes of invasive lobular breast cancer.

Michaut M, Chin SF, Majewski I, Severson TM, Bismeijer T, de Koning L, Peeters JK, Schouten PC, Rueda OM, Bosma AJ, Tarrant F, Fan Y, He B, Xue Z, Mittempergher L, Kluin RJ, Heijmans J, Snel M, Pereira B, Schlicker A, Provenzano E, Ali HR, Gaber A, O'Hurley G, Lehn S, Muris JJ, Wesseling J, Kay E, Sammut SJ, Bardwell HA, Barbet AS, Bard F, Lecerf C, O'Connor DP, Vis DJ, Benes CH, McDermott U, Garnett MJ, Simon IM, Jirström K, Dubois T, Linn SC, Gallagher WM, Wessels LF, Caldas C, Bernards R.

Sci Rep. 2016 Jan 5;6:18517. doi: 10.1038/srep18517.

24.

LIM kinase inhibitors disrupt mitotic microtubule organization and impair tumor cell proliferation.

Mardilovich K, Baugh M, Crighton D, Kowalczyk D, Gabrielsen M, Munro J, Croft DR, Lourenco F, James D, Kalna G, McGarry L, Rath O, Shanks E, Garnett MJ, McDermott U, Brookfield J, Charles M, Hammonds T, Olson MF.

Oncotarget. 2015 Nov 17;6(36):38469-86. doi: 10.18632/oncotarget.6288.

25.

Combinations of PARP Inhibitors with Temozolomide Drive PARP1 Trapping and Apoptosis in Ewing's Sarcoma.

Gill SJ, Travers J, Pshenichnaya I, Kogera FA, Barthorpe S, Mironenko T, Richardson L, Benes CH, Stratton MR, McDermott U, Jackson SP, Garnett MJ.

PLoS One. 2015 Oct 27;10(10):e0140988. doi: 10.1371/journal.pone.0140988. eCollection 2015.

26.

What role could organoids play in the personalization of cancer treatment?

Francies HE, Garnett MJ.

Pharmacogenomics. 2015;16(14):1523-6. doi: 10.2217/pgs.15.114. Epub 2015 Oct 20.

PMID:
26485224
27.

A Semi-Supervised Approach for Refining Transcriptional Signatures of Drug Response and Repositioning Predictions.

Iorio F, Shrestha RL, Levin N, Boilot V, Garnett MJ, Saez-Rodriguez J, Draviam VM.

PLoS One. 2015 Oct 9;10(10):e0139446. doi: 10.1371/journal.pone.0139446. eCollection 2015.

28.

Potent organo-osmium compound shifts metabolism in epithelial ovarian cancer cells.

Hearn JM, Romero-Canelón I, Munro AF, Fu Y, Pizarro AM, Garnett MJ, McDermott U, Carragher NO, Sadler PJ.

Proc Natl Acad Sci U S A. 2015 Jul 21;112(29):E3800-5. doi: 10.1073/pnas.1500925112. Epub 2015 Jul 10.

29.

Prospective derivation of a living organoid biobank of colorectal cancer patients.

van de Wetering M, Francies HE, Francis JM, Bounova G, Iorio F, Pronk A, van Houdt W, van Gorp J, Taylor-Weiner A, Kester L, McLaren-Douglas A, Blokker J, Jaksani S, Bartfeld S, Volckman R, van Sluis P, Li VS, Seepo S, Sekhar Pedamallu C, Cibulskis K, Carter SL, McKenna A, Lawrence MS, Lichtenstein L, Stewart C, Koster J, Versteeg R, van Oudenaarden A, Saez-Rodriguez J, Vries RG, Getz G, Wessels L, Stratton MR, McDermott U, Meyerson M, Garnett MJ, Clevers H.

Cell. 2015 May 7;161(4):933-45. doi: 10.1016/j.cell.2015.03.053.

30.

Fast randomization of large genomic datasets while preserving alteration counts.

Gobbi A, Iorio F, Dawson KJ, Wedge DC, Tamborero D, Alexandrov LB, Lopez-Bigas N, Garnett MJ, Jurman G, Saez-Rodriguez J.

Bioinformatics. 2014 Sep 1;30(17):i617-23. doi: 10.1093/bioinformatics/btu474.

31.

The evolving role of cancer cell line-based screens to define the impact of cancer genomes on drug response.

Garnett MJ, McDermott U.

Curr Opin Genet Dev. 2014 Feb;24:114-9. doi: 10.1016/j.gde.2013.12.002. Epub 2014 Mar 5. Review.

32.

Targeting MYCN in neuroblastoma by BET bromodomain inhibition.

Puissant A, Frumm SM, Alexe G, Bassil CF, Qi J, Chanthery YH, Nekritz EA, Zeid R, Gustafson WC, Greninger P, Garnett MJ, McDermott U, Benes CH, Kung AL, Weiss WA, Bradner JE, Stegmaier K.

Cancer Discov. 2013 Mar;3(3):308-23. doi: 10.1158/2159-8290.CD-12-0418. Epub 2013 Feb 21.

33.

Mcl-1 and FBW7 control a dominant survival pathway underlying HDAC and Bcl-2 inhibitor synergy in squamous cell carcinoma.

He L, Torres-Lockhart K, Forster N, Ramakrishnan S, Greninger P, Garnett MJ, McDermott U, Rothenberg SM, Benes CH, Ellisen LW.

Cancer Discov. 2013 Mar;3(3):324-37. doi: 10.1158/2159-8290.CD-12-0417. Epub 2012 Dec 28.

34.

Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells.

Yang W, Soares J, Greninger P, Edelman EJ, Lightfoot H, Forbes S, Bindal N, Beare D, Smith JA, Thompson IR, Ramaswamy S, Futreal PA, Haber DA, Stratton MR, Benes C, McDermott U, Garnett MJ.

Nucleic Acids Res. 2013 Jan;41(Database issue):D955-61. doi: 10.1093/nar/gks1111. Epub 2012 Nov 23.

35.

Systematic identification of genomic markers of drug sensitivity in cancer cells.

Garnett MJ, Edelman EJ, Heidorn SJ, Greenman CD, Dastur A, Lau KW, Greninger P, Thompson IR, Luo X, Soares J, Liu Q, Iorio F, Surdez D, Chen L, Milano RJ, Bignell GR, Tam AT, Davies H, Stevenson JA, Barthorpe S, Lutz SR, Kogera F, Lawrence K, McLaren-Douglas A, Mitropoulos X, Mironenko T, Thi H, Richardson L, Zhou W, Jewitt F, Zhang T, O'Brien P, Boisvert JL, Price S, Hur W, Yang W, Deng X, Butler A, Choi HG, Chang JW, Baselga J, Stamenkovic I, Engelman JA, Sharma SV, Delattre O, Saez-Rodriguez J, Gray NS, Settleman J, Futreal PA, Haber DA, Stratton MR, Ramaswamy S, McDermott U, Benes CH.

Nature. 2012 Mar 28;483(7391):570-5. doi: 10.1038/nature11005.

36.

Exploiting genetic complexity in cancer to improve therapeutic strategies.

Garnett MJ, McDermott U.

Drug Discov Today. 2012 Mar;17(5-6):188-93. doi: 10.1016/j.drudis.2012.01.025. Epub 2012 Feb 8.

37.

A mitotic function for the high-mobility group protein HMG20b regulated by its interaction with the BRC repeats of the BRCA2 tumor suppressor.

Lee M, Daniels MJ, Garnett MJ, Venkitaraman AR.

Oncogene. 2011 Jul 28;30(30):3360-9. doi: 10.1038/onc.2011.55. Epub 2011 Mar 14.

38.

UBE2S elongates ubiquitin chains on APC/C substrates to promote mitotic exit.

Garnett MJ, Mansfeld J, Godwin C, Matsusaka T, Wu J, Russell P, Pines J, Venkitaraman AR.

Nat Cell Biol. 2009 Nov;11(11):1363-9. doi: 10.1038/ncb1983. Epub 2009 Oct 11.

39.

Management of patients with reduced oral aperture and mandibular hypomobility (trismus) and implications for operative dentistry.

Garnett MJ, Nohl FS, Barclay SC.

Br Dent J. 2008 Feb 9;204(3):125-31. doi: 10.1038/bdj.2008.47.

PMID:
18264060
40.

Survival of resin-bonded bridgework provided for post-orthodontic hypodontia patients with missing maxillary lateral incisors.

Garnett MJ, Wassell RW, Jepson NJ, Nohl FS.

Br Dent J. 2006 Oct 21;201(8):527-34; discussion 525.

PMID:
17057683
41.

Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization.

Garnett MJ, Rana S, Paterson H, Barford D, Marais R.

Mol Cell. 2005 Dec 22;20(6):963-9.

42.

Guilty as charged: B-RAF is a human oncogene.

Garnett MJ, Marais R.

Cancer Cell. 2004 Oct;6(4):313-9. Review.

43.

Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF.

Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, Jones CM, Marshall CJ, Springer CJ, Barford D, Marais R; Cancer Genome Project.

Cell. 2004 Mar 19;116(6):855-67.

44.
45.

Mutations of the BRAF gene in human cancer.

Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA.

Nature. 2002 Jun 27;417(6892):949-54. Epub 2002 Jun 9.

PMID:
12068308
46.

ETV6-NTRK3 gene fusions and trisomy 11 establish a histogenetic link between mesoblastic nephroma and congenital fibrosarcoma.

Knezevich SR, Garnett MJ, Pysher TJ, Beckwith JB, Grundy PE, Sorensen PH.

Cancer Res. 1998 Nov 15;58(22):5046-8.

47.

Communicable disease surveillance: Notification of infectious diseases in Canada.

Sockett PN, Garnett MJ, Scott C.

Can J Infect Dis. 1996 Sep;7(5):293-5. No abstract available.

48.

Laboratory evidence of human viral and selected non-viral infections in Canada--1988.

Parker C, Weber JM, Garnett MJ.

Can Dis Wkly Rep. 1989 Oct 14;15(41):205-8. English, French. No abstract available.

PMID:
2605666
49.

Laboratory reports of chlamydial infections in Canada, 1987.

Todd MJ, Jessamine AG, Garnett MJ, Vanschepen H, Neumann PW.

Can Dis Wkly Rep. 1988 Oct 15;14(41):187-91. English, French. No abstract available.

PMID:
3072106
50.

Laboratory evidence of human viral and selected non-viral infections in Canada-1987.

Parker C, Weber J, Garnett MJ, Neumann P.

Can Dis Wkly Rep. 1988 Sep 17;14(37):165-8. English, French. No abstract available.

PMID:
3266584

Supplemental Content

Loading ...
Support Center